Posts Tagged ‘PPD’
PPD Named ‘Most Innovative CRO’ by Triangle Business Journal
Honors PPD’s development and implementation of innovative customer solutions during COVID-19 pandemic WILMINGTON, N.C. has been named “Most Innovative CRO” by North Carolina’s Triangle Business Journal, recognizing the global contract research organization’s strong performance in a year shaped by the COVID-19 pandemic. PPD’s significant investments to expand capabilities for patient recruitment for clinical trials, investigator sites, laboratories,…
Read MorePPD Opens Multipurpose Clinical Research Laboratory in Suzhou, China
SUZHOU, CHINA – PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, held a grand opening ceremony for its new multipurpose laboratory in Suzhou, China, to support Western and China-based pharmaceutical and biotech companies managing China research studies. The 67,000-square-foot facility in the Suzhou New District, Jiangsu Province, offers bioanalytical, biomarker and vaccine laboratory services to…
Read MoreCRO Leadership Awards Recognize PPD for Excellence for 10th Consecutive Year
WILMINGTON, N.C. – PPD, Inc. (Nasdaq: PPD) has been recognized for excellence in the CRO Leadership Awards for the 10th consecutive year, earning praise for its clinical research capabilities and customer compatibility in a survey of pharmaceutical and biotech professionals conducted for Clinical Leader and Life Science Leader magazines. A leading global contract research organization (CRO), PPD serves a wide range of customers with…
Read MorePPD Named “Best CRO” at Vaccine Industry Excellence Awards
WILMINGTON, N.C. – PPD, Inc. (Nasdaq: PPD) was named “Best Contract Research Organization” at the 14th annual Vaccine Industry Excellence (ViE) Awards during the 2021 World Vaccine Congress. Accelerated Enrollment Solutions (AES), a business of PPD, received the honor of “highly commended” in the category of “Best Clinical Trial Network.” “When it comes to helping customers develop safe and effective vaccines, our dedicated…
Read MorePPD to Expand GMP Lab in Ireland to Enhance Biopharmaceutical Testing Capabilities
Adding cell and gene therapy capabilities to support growing customer need WILMINGTON, N.C. – PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, is expanding its Athlone, Ireland, GMP (good manufacturing practices) laboratory, significantly increasing the size of its current facility and adding cell and gene therapy testing to the operation’s portfolio of services. The expansion…
Read MorePPD and Science 37® Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development
Innovative approach enables PPD to deploy studies utilizing Science 37’s SaaS Platform WILMINGTON, N.C. & LOS ANGELES, PPD, Inc. (Nasdaq: PPD), a leading global contract research organization (CRO), and Science 37, developer of the Decentralized Clinical Trial Operating System™ (DCT OS), today announced an innovative collaboration in which PPD will be fully enabled to design, build, test, implement and execute…
Read MoreThermo Fisher Scientific set to acquire PPD
Further expands service offering to pharma and biotech customers WALTHAM, Mass. and WILMINGTON, N.C., — Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, and PPD, Inc. (Nasdaq: PPD) (“PPD”), a leading global provider of clinical research services to the pharma and biotech industry, today announced that their boards of directors have approved…
Read MorePPD Announces First Quarter 2021 Earnings Conference Call
WILMINGTON, N.C., a leading global contract research organization, will host a conference call on Wednesday, April 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its first quarter 2021 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD’s…
Read MorePPD and Clinical Ink Collaborate on Innovative Process for Lupus Assessment and Near Real-Time Access to Endpoint Data
WILMINGTON, N.C. – PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, and Clinical Ink, a global clinical technology company, have jointly developed a systemic lupus erythematosus (SLE) assessment review process to simplify operationalizing clinical trials for this chronic autoimmune disease. The companies’ collaborative approach focuses on enhancing data quality and research site personnel experiences and efficiencies, in turn supporting…
Read MorePPD Named a Leader in Digital Clinical Trial Solutions by ISG
Recognized for comprehensive strengths in the design, deployment of decentralized solutions WILMINGTON, N.C., PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, has been recognized for industry leadership in digital and decentralized clinical trial solutions by Information Services Group (ISG), a leading global technology research and advisory firm. ISG recognized PPD as an ISG Provider…
Read More